The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count

Fertility and Sterility

Volumn 91, Issue 3, 2009, Pages 705-714

  Broer, Simone L ^a   Mol, Ben Willem J ^b   Hendriks, Dave ^a   Broekmans, Frank J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antimullerian hormone; antral follicle count; IVF; meta analysis; poor response; pregnancy

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ANTRAL FOLLICLE COUNT; ARTICLE; CELL COUNT; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FERTILIZATION IN VITRO; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OUTCOME ASSESSMENT; OVARY FUNCTION; PREDICTION; PREGNANCY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TERTIARY HEALTH CARE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVARIAN FOLLICLE; OVARIAN FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY RATE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 61349180236     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.12.013     Document Type: Article

References (57)

1. Leridon H. Demographic effects of the introduction of steroid contraception in developed countries. Hum Reprod Update 12 (2006) 603-616
2. Spira A. The decline of fecundity with age. Am J.Human Biol Suppl 1 (1988) 15-22
3. Wood J.W. Fecundity and natural fertility in humans. Oxf Rev Reprod Biol 11 (1989) 61-109
4. te Velde E.R., and Pearson P.L. The variability of female reproductive aging. Hum Reprod Update 8 (2002) 141-154
5. Gougeon A., Echochard R., and Thalabard J.C. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of nongrowing and early- growing follicles in aging women. Biol Reprod 50 (1994) 653-663
6. Broekmans F.J., Kwee J., Hendriks D.J., Mol B.W., and Lambalk C.B. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12 (2006) 685-718
7. Klinkert E.R., Broekmans F.J., Looman C.W., and te Velde E.R. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil Steril 81 (2004) 1247-1253
8. Hendriks D.J., Kwee J., Mol B.W., te Velde E.R., and Broekmans F.J. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 87 (2007) 764-775
9. de Koning C.H., Benjamins T., Harms P., Homburg R., van Montfrans J.M., Gromoll J., et al. The distribution of FSH receptor isoforms is related to basal FSH levels in subfertile women with normal menstrual cycles. Hum Reprod 21 (2006) 443-446
10. Lashen H., Ledger W., Lopez-Bernal A., and Barlow D. Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile?. Hum Reprod 14 (1999) 964-969
11. van Disseldorp J., Eijkemans M.J., Klinkert E.R., te Velde E.R., Fauser B.C., and Broekmans F.J. Cumulative live birth rates following IVF in 41- to 43-year-old women presenting with favourable ovarian reserve characteristics. Reprod Biomed Online 14 (2007) 455-463
12. Hendriks D.J., Mol B.W., Bancsi L.F., te Velde E.R., and Broekmans F.J. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 83 (2005) 291-301
13. Lee M.M., Donahoe P.K., Hasegawa T., Silverman B., Crist G.B., Best S., et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81 (1996) 571-576
14. Weenen C., Laven J.S., Von Bergh A.R., Cranfield M., Groome N.P., Visser J.A., et al. Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10 (2004) 77-83
15. Fanchin R., Schonauer L.M., Righini C., Frydman N., Frydman R., and Taieb J. Serum antimullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 18 (2003) 328-332
16. La Marca A., Malmusi S., Giulini S., Tamaro L.F., Orvieto R., Levratti P., et al. Anti-mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19 (2004) 2738-2741
17. Hudson P.L., Dougas I., Donahoe P.K., Cate R.L., Epstein J., Pepinsky R.B., et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J.Clin Endocrinol Metab 70 (1990) 16-22
18. de Vet A., Laven J.S., de Jong F.H., Themmen A.P., and Fauser B.C. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77 (2002) 357-362
19. Gruijters M.J., Visser J.A., Durlinger A.L., and Themmen A.P. Anti-mullerian hormone and its role in ovarian function. Mol Cell Endocrinol 211 (2003) 85-90
20. van Rooij I.A., Broekmans F.J., te Velde E.R., Fauser B.C., Bancsi L.F., Jong F.H., et al. Serum antimullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17 (2002) 3065-3071
21. Hehenkamp W.J., Looman C.W., Themmen A.P., de Jong F.H., te Velde E.R., and Broekmans F.J. Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J.Clin Endocrinol Metab 91 (2006) 4057-4063
22. La Marca A., Stabile G., Artenisio A.C., and Volpe A. Serum antimullerian hormone throughout the human menstrual cycle. Hum Reprod 21 (2006) 3103-3107
23. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., and Shelden R.M. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77 (2002) 468-471
24. van Rooij I.A., de Jong E., Broekmans F.J., Looman C.W., Habbema J.D., and te Velde E.R. High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. Fertil Steril 81 (2004) 1478-1485
25. Hazout A., Bouchard P., Seifer D.B., Aussage P., Junca A.M., and Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82 (2004) 1323-1329
26. Littenberg B., and Moses L.E. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 13 (1993) 313-321
27. Midgette A.S., Stukel T.A., and Littenberg B. A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic-summary point estimates. Med Decis Making 13 (1993) 253-257
28. Moses L.E., Shapiro D., and Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12 (1993) 1293-1316
29. Muttukrishna S., McGarrigle H., Wakim R., Khadum I., Ranieri D.M., and Serhal P. Antral follicle count, antimullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?. BJOG 112 (2005) 1384-1390
30. Muttukrishna S., Suharjono H., McGarrigle H., and Sathanandan M. Inhibin B and antimullerian hormone: markers of ovarian response in IVF/ICSI patients?. BJOG 111 (2004) 1248-1253
31. Penarrubia J., Fabregues F., Manau D., Creus M., Casals G., Casamitjana R., et al. Basal and stimulation day 5 antimullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 20 (2005) 915-922
32. Tremellen K.P., Kolo M., Gilmore A., and Lekamge D.N. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol 45 (2005) 20-24
33. Eldar-Geva T., Ben Chetrit A., Spitz I.M., Rabinowitz R., Markowitz E., Mimoni T., et al. Dynamic assays of inhibin B, antimullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 20 (2005) 3178-3183
34. McIlveen M., Skull J.D., and Ledger W.L. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 22 (2007) 778-785
35. Ficicioglu C., Kutlu T., Baglam E., and Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 85 (2006) 592-596
36. La Marca A., Giulini S., Tirelli A., Bertucci E., Marsella T., Xella S., et al. Anti-mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22 (2007) 766-771
37. Ebner T., Sommergruber M., Moser M., Shebl O., Schreier-Lechner E., and Tews G. Basal level of antimullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 21 (2006) 2022-2026
38. Smeenk J.M., Sweep F.C., Zielhuis G.A., Kremer J.A., Thomas C.M., and Braat D.D. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 87 (2007) 223-226
39. Freour T., Mirallie S., Bach-Ngohou K., Denis M., Barriere P., and Masson D. Measurement of serum antimullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 375 (2007) 162-164
40. Kwee J, Schats R, McDonnell J, Themmen AP, de Jong FH, Lambalk CB. Evaluation of AMH as test for the prediction of ovarian reserve. Fertil Steril. Published online October 17, 2007. [E-pub ahead of print.]
41. Cook C.L., Siow Y., Taylor S., and Fallat M.E. Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 73 (2000) 859-861
42. Hansen K.R., Morris J.L., Thyer A.C., and Soules M.R. Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting. Fertil Steril 80 (2003) 577-583
43. Scheffer G.J., Broekmans F.J., Bancsi L.F., Habbema J.D., Looman C.W., and te Velde E.R. Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts. Ultrasound Obstet Gynecol 20 (2002) 270-275
44. Pache T.D., Wladimiroff J.W., de Jong F.H., Hop W.C., and Fauser B.C.J.M. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril 54 (1990) 638-642
45. Kwee J., Elting M.W., Schats R., Bezemer P.D., Lambalk C.B., and Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. Hum Reprod 18 (2003) 1422-1427
46. Boomsma C.M., and Macklon N.S. What can the clinician do to improve implantation?. Reprod Biomed Online 13 (2006) 845-855
47. Templeton A., Morris J.K., and Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet 348 (1996) 1402-1406
48. van der Gaast M.H., Eijkemans M.J., van der Net J.B., de Boer E.J., Burger C.W., van Leeuwen F.E., et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 13 (2006) 476-480
49. Mol B.W., Verhagen T.E., Hendriks D.J., Collins J.A., Coomarasamy A., Opmeer B.C., et al. Value of ovarian reserve testing before IVF: a clinical decision analysis. Hum Reprod 21 (2006) 1816-1823
50. Popovic-Todorovic B., Loft A., Bredkjaeer H.E., Bangsboll S., Nielsen I.K., and Andersen A.N. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a "standard" dose of 150 IU/day in "standard" patients undergoing IVF/ICSI treatment. Hum Reprod 18 (2003) 2275-2282
51. Klinkert E.R., Broekmans F.J., Looman C.W., Habbema J.D., and te Velde E.R. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 20 (2005) 611-615
52. Tarlatzis B.C., Zepiridis L., Grimbizis G., and Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 9 (2003) 61-76
53. de Koning C.H., Popp-Snijders C., Martens F., and Lambalk C.B. Falsely elevated follicle-stimulating hormone levels in women with regular menstrual cycles due to interference in immunoradiometric assay. J.Assist Reprod Genet 17 (2000) 457-459
54. Lambalk C.B., and de Koning C.H. Interpretation of elevated FSH in the regular menstrual cycle. Am J Human Biol 30 (1998) 215-220
55. Hendriks D, te Velde ER, Looman CW, Bancsi LF, Broekmans FJ. The role of poor response in the prediction of the cumulative ongoing pregnancy rate in in vitro fertilisation. In: Dynamic and basal ovarian reserve tests for outcome prediction in IVF: comparisons and meta-analyses. [Academic thesis, University Utrecht]. 2005:162-179.
56. Broekmans F.J., Knauff E.A., te Velde E.R., Macklon N.S., and Fauser B.C. Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metab 18 (2007) 58-65
57. Hefler L.A., Grimm C., Bentz E.K., Reinthaller A., Heinze G., and Tempfer C.B. A model for predicting age at menopause in white women. Fertil Steril 85 (2006) 451-454